CADILA HEALTHCARE LTD. - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate for the quarter ended on June 30, 2020.10-07-2020
10-07-2020
Coronavirus vaccine news update: Bharat Biotech, Zydus Cadila set for trials; SII expects nod in 6 months
Coronavirus vaccine update: Twelve hospitals have been chosen for COVAXIN trials in the country. Bharat Biotech's COVAXIN is undergoing quality and safety tests before the doses are administered to volunteers08-07-2020
Zydus Cadila gets approval to test COVID-19 drug in Mexico
The company said it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients06-07-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives approval from COFERIS, Mexico to study Desidustat in the management of COVID-1906-07-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting04-07-2020
Covid-19 crisis: Race to develop vaccine gets a booster as field widens
On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.04-07-2020
Cadila Healthcare share rises 5% on nod for human trial of Covid-19 vaccine
Cadila Healthcare stock trades mere points away from its 52-week high of Rs 383.65. Cadila Healthcare stock has risen 4.73% in the last 2 sessions03-07-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus' vaccine for COVID-19 (ZyCoV-D) successfully completes preclinical development and receives permission to initiate human clinical trials03-07-2020
CADILA HEALTHCARE LTD. - 532321 - Closure of Trading Window
Intimation of Trading Window Closure25-06-2020
Zydus Cadila gets USFDA nod to market generic antihistamine tablets
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Meclizine hydrochloride tablets in the strengths of 12.5 mg and 25 mg, the company said in a statement.24-06-2020